Insider holders · CIK 0000920148
LABCORP HOLDINGS INC. · LH
Every insider with a reported Table I holding at this company, ranked by their last-reported share count. A balance is only as fresh as its filing — the report date sits next to every row on purpose. ← Back to activity
| Insider | Direct shares | Indirect shares | Total reported | Last report (ET) | From |
|---|---|---|---|---|---|
| David P KingPresident & CEO | 246,281 | 34,462 | 280,743 | Feb 14, 2019 · 4:44 pm EST | Form 4 |
| Adam H SchechterPresident & CEO | 102,565 | — | 102,565 | Aug 12, 2026 · 2:31 pm EDT | Form 4 |
| Jean-Luc BelingardDirector | 34,013 | — | 34,013 | Feb 14, 2019 · 5:01 pm EST | Form 4 |
| F Samuel Eberts IIIChief Legal Officer, Secretary | 28,823 | — | 28,823 | Feb 14, 2019 · 4:10 pm EST | Form 4 |
| James T. Boyle Jr.EVP,CEO of LabCorp Diagnostics | 23,454 | — | 23,454 | Apr 1, 2016 · 1:11 pm EDT | Form 4 |
| Glenn A EisenbergChief Financial Officer, EVP | 20,235 | — | 20,235 | Feb 14, 2019 · 4:05 pm EST | Form 4 |
| Deborah L KellerCEO, Covance Drug Development | 19,754 | — | 19,754 | Mar 15, 2016 · 1:36 pm EDT | Form 4 |
| John D RatliffCEO, Covance Drug Development | 15,601 | 80 | 15,681 | Feb 14, 2019 · 4:08 pm EST | Form 4 |
| Robert E Mittelstaedt Jr.Director | 15,209 | — | 15,209 | Feb 14, 2019 · 4:25 pm EST | Form 4 |
| Joseph L HerringCEO of Covance Drug Division | 10,404 | 4,508 | 14,912 | Aug 4, 2015 · 2:15 pm EDT | Form 4 |
| Edward T DodsonPrincipal Accounting Officer | 9,912 | — | 9,912 | Feb 14, 2019 · 4:13 pm EST | Form 4 |
| Peter M NeupertDirector | 8,769 | — | 8,769 | Feb 14, 2019 · 4:37 pm EST | Form 4 |
| Lance BerberianSVP, Chief Information Officer | 8,756 | — | 8,756 | Feb 14, 2019 · 4:02 pm EST | Form 4 |
| R Sanders WilliamsDirector | 7,886 | — | 7,886 | Feb 14, 2019 · 4:18 pm EST | Form 4 |
| Garheng KongDirector | 7,225 | — | 7,225 | Feb 14, 2019 · 4:27 pm EST | Form 4 |
| Amy B. SummyEVP, Chief Marketing Officer | 6,956 | — | 6,956 | Aug 6, 2026 · 8:26 am EDT | Form 4 |
| Bryan T VaughnEVP and President, Diagnostics | 6,746 | — | 6,746 | Jul 6, 2026 · 9:36 am EDT | Form 4 |
| Kerrii B AndersonDirector | 6,563 | 144 | 6,707 | Aug 18, 2026 · 8:10 am EDT | Form 4 |
| Mark E BrecherCMO, LabCorp Diagnostics | 5,511 | — | 5,511 | Apr 1, 2015 · 8:35 pm EDT | Form 4 |
| Dwight Gary GillilandDirector | 4,539 | — | 4,539 | Feb 14, 2019 · 4:33 pm EST | Form 4 |
| Lisa J UthgenanntChief Human Resources Officer | 4,489 | — | 4,489 | Feb 14, 2019 · 3:58 pm EST | Form 4 |
| Kathryn W KyleEVP, Chief Legal Officer | 3,904 | — | 3,904 | Jul 6, 2026 · 9:37 am EDT | Form 4 |
| Richelle P ParhamDirector | 3,861 | — | 3,861 | Feb 14, 2019 · 4:26 pm EST | Form 4 |
| M. Huff GaryCEO, LabCorp Diagnostics | 1,850 | — | 1,850 | Sep 6, 2018 · 10:21 am EDT | Form 4 |
| Peter J WilkinsonSVP, Chief Accounting Officer | 1,770 | — | 1,770 | Aug 5, 2026 · 11:17 am EDT | Form 4 |
| Sandra D van der VaartSVP, Global General Counsel | 908 | — | 908 | Feb 22, 2019 · 1:43 pm EST | Form 3 |
| Brian J CaveneySVP, Chief Medical Officer | 151 | — | 151 | Feb 14, 2019 · 3:59 pm EST | Form 4 |
Balances come from each insider’s most recent filing that reports a Table I holding; an insider who left the company years ago still appears with their last-known figure and its date. Indirect totals collapse multiple vehicles (trusts, LLCs) into one number — open the filing for the breakdown. Shares as filed, not split-adjusted.